Chronic Kidney Disease Market: Global Industry Analysis and Forecast (2022-2029) Trends, Statistics, Dynamics, Segmentation by Type of Treatment, End User, Route of Administration and Region

The Global Chronic Kidney Disease Market size reached USD 65.86 Bn in 2022 and is expected to reach USD 93.91 Bn by 2029, growing at a CAGR of 5.2 % during the forecast period.

The Chronic Kidney Disease (CKD) market is witnessing a significant paradigm shift in the current healthcare landscape. As of the latest available data in 2022, the global CKD market has been steadily growing, primarily due to the increasing prevalence of CKD, a rise in aging populations, and a surge in risk factors such as hypertension and diabetes. The market's growth is further driven by advances in early detection and management, emphasizing the importance of disease awareness and education, and the development of novel therapies and treatments. Key players in the market, such as Amgen, AstraZeneca, and Bayer, have been actively involved in research and development of innovative drugs, including SGLT2 inhibitors, mineralocorticoid receptor antagonists, and erythropoiesis-stimulating agents. These efforts aim to not only slow the progression of CKD but also reduce the associated risks and complications, such as cardiovascular events and end-stage renal disease. Moreover, the introduction of precision medicine and telehealth solutions to monitor CKD patients remotely signifies a shift towards more personalized and accessible care, which is expected to further shape the CKD market's future trajectory as it continues to address the growing global burden of chronic kidney disease.

Chronic kidney disease is a significant global health problem, affecting around 1 in 10 people worldwide. According to the Centres for Disease Control and Prevention in the United States, approximately 37 million people are estimated to have chronic kidney disease. Nearly 786,000 people in the United States are living with end-stage renal disease (ESRD), 71% on dialysis and 29% with a kidney transplant. CKD is more common in older adults, women, and people of African American, Hispanic, or Native American descent. Early detection and treatment of CKD slow the progression of the disease and improve outcomes for affected individuals. The Chronic Kidney Disease market is segmented into various categories such as diagnostic tests, pharmaceuticals, and dialysis equipment. The increasing prevalence of CKD, rise in the number of patients requiring dialysis and kidney transplants, and the increasing adoption of novel treatments and therapies are expected to drive the chronic kidney disease market during the forecast period.
To know about the Research Methodology :- Request Free Sample Report
Chronic Kidney Disease Market Dynamics:
The Advances in Medical Technology and the Development of New Drugs and Therapies to Drive Chronic Kidney Disease Market Growth

The increasing prevalence of CKD, often linked to risk factors like diabetes and hypertension, has contributed to a growing patient pool; for instance, over 37 million Americans have CKD, according to the National Kidney Foundation. Additionally, the aging population in developed countries is more susceptible to CKD, further bolstering market demand. Technological advancements, such as wearable devices and telehealth solutions, have transformed CKD management, with companies like Renalytix AI leveraging artificial intelligence for early detection and monitoring. Heightened awareness campaigns and educational initiatives, exemplified by organizations like the American Kidney Fund, have improved early CKD detection, driving the need for medical interventions and management products. Innovative therapies, such as the FDA-approved dapagliflozin for CKD patients, have expanded the treatment landscape.

The increasing global healthcare expenditure, governments and private entities invest in healthcare infrastructure, fueling the accessibility to CKD treatments. Precision medicine and data-driven approaches, as seen with companies like Diaceutics, personalize CKD patient treatments, contributing to market growth. The surge in clinical trials for CKD treatments, led by key players like Akebia Therapeutics, fuels research and development investments. The emphasis on preventive care and integration of preventive measures into healthcare systems reduces CKD risks and augments market expansion. The global burden of CKD, as emphasized by initiatives like World Kidney Day, is pushing for improved access to care and increased research efforts.

Government policies and initiatives, such as the "Advancing American Kidney Health" initiative in the United States, promote early intervention and access to new treatments, further stimulating market growth. This includes the use of stem cells and other advanced therapies that have the potential to revolutionize the treatment of CKD. Thus, the advances in medical technology and the development of new drugs and therapies are expected to drive growth in the Chronic Kidney Disease Market by offering new and improved treatment options for patients, improving patient outcomes, and reducing the burden of the disease.

Prevalence Rates for Chronic Kidney Disease in Selected Countries Worldwide (Per 100000 Population)

The High Cost of Treatment and the Patent Expiry of Many Drugs

High treatment costs, exemplified by the substantial expenses associated with dialysis and transplantation in the United States, can limit access to care, while limited access to quality healthcare services in remote or low-income areas, as seen in sub-Saharan Africa, can lead to delayed or inadequate CKD management. Late diagnosis, often due to asymptomatic early stages, can result in complications and increased healthcare costs. The coexistence of CKD with comorbidities, limited public awareness, health disparities among populations, the shortage of donor kidneys for transplantation, medication non-adherence, psychosocial impacts, and global inequalities in CKD care are all significant hurdles that affect patient outcomes and the expansion of the CKD market. A potential restraint for the CKD market could be the expiration of patents on existing medications and treatments.

When patents expire, generic versions of drugs become available, leading to increased competition and potentially reduced prices for these treatments. While this can benefit patients by making medications more affordable, it can be a challenge for pharmaceutical companies that have relied on exclusivity to drive revenue. The expiration of patents may impact their ability to maintain high-profit margins, potentially reducing incentives for further research and development in the CKD treatment space. This challenge underscores the importance of ongoing innovation and the development of novel therapies to maintain market competitiveness in the face of patent expirations.
Telemedicine to AI are Transformative Trends and Opportunities Shaping the Healthcare Industry
The healthcare industry presents a spectrum of growth opportunities driven by evolving trends and technological advancements. The expanding acceptance of digital health and telemedicine, exemplified by Teladoc Health, signifies the potential for remote healthcare services. Advances in remote patient monitoring, represented by BioTelemetry, offer avenues for managing chronic conditions. The era of personalized medicine, as showcased caters to individual genetic profiles. Interoperable digital health records, supported by companies like Epic Systems, enhance patient data management. Artificial intelligence (AI) is transforming healthcare through predictive analytics and diagnosis, led by IBM Watson Health.

Teletherapy platforms like Talkspace and BetterHelp capitalize on the growing demand for mental health services. Pharmaceutical innovations, notably mRNA technology in COVID-19 vaccines by Pfizer and Moderna, are revolutionizing drug development. The aging population drives the growth of home healthcare services, with companies like Amedisys expanding their offerings. Health and wellness apps empower individuals to take control of their well-being, typified by MyFitnessPal, and preventive healthcare services, including vaccinations and screenings, are evolving to address changing healthcare needs through providers like CVS and Walgreens. These opportunities reflect the industry's adaptability to emerging technologies and patient-centric approaches. Chronic Kidney Disease (CKD) a Silent Epidemic in the United States.
Chronic Kidney Disease Market Segment Analysis:
Based on type, the market has been divided into Drugs, Blood Test, ACE Inhibitors, Dialysis, Transplantation of Kidneys, and Others. Among these, the Drugs sub-segment is projected to generate the maximum revenue in 2022.The chronic kidney disease (CKD) drugs segment has established itself as a pivotal component of the pharmaceutical industry, reflecting its substantial contribution to the global healthcare landscape.

The increasing prevalence of CKD is a potent growth driver. The global burden of CKD is on the rise, with millions affected, particularly in the United States where over 37 million adults are believed to have CKD. This mounting public health concern has heightened the demand for effective treatments and pharmaceutical interventions. Additionally, the aging population is contributing to the segment's expansion. Elderly individuals are more susceptible to kidney-related health issues, and as demographic shifts continue, the prevalence of CKD is expected to increase. Pharmaceutical companies specializing in CKD drugs are well-positioned to cater to the unique needs of this demographic. Crucially, the development of novel drugs with improved efficacy and safety profiles is transforming CKD treatment. These innovative medications not only slow CKD progression but also reduce associated risks and complications, promising better outcomes for patients. For instance, the recommendation for Finerenone, also known as Kerendia and manufactured by Bayer, as a treatment option for adults with stage 3 and 4 chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM) and albuminuria is regarded as a significant stride forward in therapeutic approaches, according to the MMR analysis.



Treatment
Description


Home Dialysis
Home dialysis allows kidney disease patients to receive treatment at home. There are two main types: peritoneal dialysis (PD) and home hemodialysis (HHD). Peritoneal dialysis uses the patient's abdominal lining to filter waste, while home hemodialysis uses a machine for filtering, similar to in-center hemodialysis.


Artificial Intelligence (AI)
AI has the potential to revolutionize kidney disease diagnosis and treatment. It can analyze medical data, identify patterns, and predict the risk of developing kidney disease, aiding in early detection. AI can also predict disease progression and personalize treatment plans.


Immersive Technology
Immersive technologies like virtual reality (VR) and augmented reality (AR) can assist in kidney disease diagnosis, treatment, and education. They allow for practicing procedures, such as kidney transplantation, and provide real-time guidance during surgeries.


Advanced Renal Testing
Advanced renal testing comprises diagnostic tests to assess kidney function and detect abnormalities. Common tests include Glomerular Filtration Rate (GFR) testing to evaluate filtration efficiency, Blood Urea Nitrogen (BUN) testing as an indicator of kidney function, and urinalysis to detect abnormal substances in urine.


Genomic Engineering
Genomic engineering methods like CRISPR-Cas9 gene editing can correct mutations responsible for inherited kidney diseases. Gene therapy can introduce healthy genes into deficient kidney cells, potentially restoring normal function.


Kidney Diseases Statistics
Worldwide, chronic kidney disease (CKD) affects 13.4% of the population. In the US, over 1 in 7 adults (37 million) have CKD, with 1 in 3 people with diabetes and 1 in 5 with high blood pressure affected. It's noteworthy that 9 in 10 CKD patients are unaware of their condition.




Chronic Kidney Disease Market Regional Insights
The North America Chronic Kidney Disease market is expected to grow at a CAGR of 23.5% during the forecast period. The United States is one of the largest corn-producing countries in the world, and corn is widely grown in many regions of North America. The high prevalence of chronic kidney disease in the region, coupled with the availability of advanced healthcare infrastructure and medical expertise has contributed to the growth of the chronic kidney disease market in North America.

The United States has the largest market with over 37 million people estimated to be living with chronic kidney disease. The Canadian government has also taken initiatives to improve the diagnosis and management of CKD, which has further boosted the demand for the Chronic Kidney Disease Market in the country. Some of the key players in the North American CKD market include Amgen Inc., AbbVie Inc., Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, and Johnson & Johnson. These companies are involved in developing and marketing a range of products and therapies for the treatment of chronic kidney diseases such as medications for anemia, mineral and bone disorders, and hypertension, as well as dialysis products and services. They invest heavily in research and development to introduce new and innovative therapies to improve the quality of life of patients with chronic kidney disease.

The Chronic Kidney Disease market in the Asia Pacific region is expected to experience significant growth during the forecast period. The growing prevalence of CKD, a rise in the geriatric population, increasing awareness about the disease, and government initiatives to improve patient outcomes are expected to drive market growth in this region. One of the leading key players in the Asia Pacific Chronic Kidney Disease Market is Fresenius Medical Care AG & Co. KGaA. The company offers a range of products and services for the treatment of CKD, including hemodialysis machines, dialyzers, bloodline systems, peritoneal dialysis systems, and services for chronic care management. The company has a significant presence in the region, with operations in countries such as China, India, Japan, and Australia, among others. It is actively involved in research and development to introduce new and innovative therapies to improve patient outcomes.
Report Scope:
The report provides a quantitative analysis of the current chronic kidney disease market drivers, restraints, trends, estimations, and opportunities of the market to identify the prevailing opportunities in the market during the forecast period. PORTER's five forces analysis shows the ability of buyers and suppliers to make profit-oriented strategic decisions and build their supplier-buyer network. In-depth analysis as well as the market size and segmentation assist in determining the current chronic kidney disease market potential. Some factors that are supposed to affect the business positively or negatively have been analyzed in this report which will give a clear futuristic view of the industry to the decision-makers.

The report presents a comprehensive analysis of the global chronic kidney disease market to the stakeholders who want to invest in this market. The report includes past and current scenarios of the market with the forecasted market size. The report covers all the aspects of the market with a thorough study of key players that include market leaders, followers, and new entrants.

The report contains strategic profiling of top key players in the market, a wide-ranging analysis of their core competencies, and their strategies like new product launches, growths, agreements, joint ventures, partnerships, and acquisitions that apply to the businesses. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the internal or local market make the report investor’s guide. They are continuously strategizing on mergers & acquisitions for the expansion of their market share and growth opportunities during the forecast period.
Competitive Landscape:
Renowned pharmaceutical companies such as Amgen, Roche, and Pfizer dominate the landscape, leveraging their research and development capabilities to introduce innovative therapies for CKD patients, including novel medications that target specific pathways and address unmet medical needs. Furthermore, established medical device manufacturers such as Fresenius Medical Care and Baxter International play a crucial role in the CKD market, providing dialysis equipment and services vital for end-stage renal disease (ESRD) patients. Additionally, the market hosts an assortment of biotech companies like Ardelyx, FibroGen, and Reata Pharmaceuticals, which are dedicated to advancing CKD treatment options, including small molecules and biologics. This competitive environment is also witnessing the emergence of startups specializing in digital health, telemedicine, and remote patient monitoring, facilitating comprehensive CKD management and patient engagement.

The collaboration between these diverse players, along with academic institutions, fosters a dynamic ecosystem that promotes innovation and the development of advanced therapies and treatment modalities, thus enhancing the quality of life and outcomes for CKD patients worldwide. The competitive landscape in the CKD market is shaped by a relentless pursuit of groundbreaking therapies and holistic care approaches, driven by the collective commitment to mitigate the burden of this pervasive and complex disease.
Chronic Kidney Disease Market Scope: Inquire before buying



Chronic Kidney Disease Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 65.86 Bn.


Forecast Period 2023 to 2029 CAGR:
5.2%
Market Size in 2029:
US $ 93.91 Bn.


 Segments Covered:
by Type of Treatment
Drugs
Blood Test
ACE Inhibitors
Dialysis
Transplantation of Kidneys
Others


by End User
Hospitals & Clinics
Ambulatory Surgery Centres (ASCs)
Dialysis Centres
Others


by Route of Administration
Oral
Intravenous
Subcutaneous



Chronic Kidney Disease Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Chronic Kidney Disease Market Key Players
1. Amgen Inc.
2. ProKidney
3. Reata Pharmaceuticals, Inc
4. Abbott Laboratories
5. F. Hoffmann-La Roche Ltd
6. Fresenius Medical Care AG & Co. KGaA
7. Siemens Healthineers
8. Cincor Pharma
9. Allena Pharmaceuticals
10.DiaMedica Therapeutics Inc
11.Lexicon Pharmaceuticals
12.AbbVie Inc.
13.AstraZeneca plc
14.Bayer AG
15.Bristol-Myers Squibb Company
16.GlaxoSmithKline plc
17.Johnson & Johnson
18.Keryx Biopharmaceuticals, Inc.
19.Kissei Pharmaceutical Co., Ltd.
20.Merck & Co. Inc.
21.Novartis International AG
22.Pfizer Inc
23.Sanofi SA
24.Teva Pharmaceutical Industries Ltd.
25.Roche Holding AG

FAQs:

1. Who are the key players in the market?
Ans. Pfizer Inc., Amgen, Inc. and Abbott are the major companies operating in the chronic kidney disease market.

2. Which Type of Treatment segment dominates the chronic kidney disease market?
Ans. The Drug segment accounted for the largest share of the global chronic kidney disease market in 2022.

3. How big is the chronic kidney disease market?
Ans. The Global market size reached USD 65.86 Bn in 2022 and is expected to reach USD 93.91 Bn by 2029, growing at a CAGR of 5.2 % during the forecast period.

4. What are the key regions in the global chronic kidney disease market?
Ans. Based On the region, the Chronic Kidney Disease Market has been classified into North America, Europe, Asia Pacific, the Middle, East and Africa, and Latin America. North America dominates the global market.

5. What is the study period of this market?
Ans. The Global Market is studied from 2022 to 2029.